$HOPHF News
Last published 3y ago
- 3y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Total Voting RightsACCESS NewswireTotal Voting RightsLONDON, UK / ACCESSWIRE / February 28, 2023 / Hemogenyx Pharmaceuticals plc , the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Half-year ReportACCESS NewswireHalf-year ReportInterim Results for the period ended 30 June 2022 LONDON, UK / ACCESSWIRE / September 29, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the Standard Listed biopharmaceutical group developing therapies designed to transform blood disea
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Presentation at H.C. Wainwright Global ConferenceACCESS NewswireLONDON, UK / ACCESSWIRE / September 1, 2022 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright 24th Annual G
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Appointment of Director of QualityACCESS NewswireQuality System Expert Joins Hemogenyx Pharmaceuticals as Director of Quality LONDON, UK / ACCESSWIRE / August 22, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, an
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Approval and Issuance of Antibody PatentACCESS NewswireApproval and Issuance of Chinese Bi-specific Antibody Patent LONDON, UK / ACCESSWIRE / August 15, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to anno
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Appointment of Medical DirectorACCESS NewswireOne of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director LONDON, UK / ACCESSWIRE / August 10, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapi
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Director/PDMR ShareholdingACCESS NewswireLONDON, UK / ACCESSWIRE / May 30, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 e
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Immuno-Oncology Summit Europe PresentationACCESS NewswireLONDON, UK / ACCESSWIRE / May 16, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce its participation in the Immuno-Oncology Summit Europe 2022, at which Dr Vladislav Sandler will make a presentation entitled "Anti-FLT3 CAR-T and Bis
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting RequestACCESS NewswireLONDON, UK / ACCESSWIRE / February 16, 2022 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces H.C. Wainwright Bioconnect ConferenceACCESS NewswireLONDON, UK / ACCESSWIRE / January 5, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Confe
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Hemo-CAR-T partnership with WuXi ATUACCESS NewswirePartnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme LONDON, UK / ACCESSWIRE / December 20, 2021 / Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies' ("WuXi ATU")
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting RequestACCESS NewswireLONDON, UK / ACCESSWIRE / December 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce significant progress in relation to moving its lead pro
- 4y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Convertible Loans RepaymentACCESS NewswireHemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Convertible Loans Repayment LONDON, UK / ACCESSWIRE / November 24, 2021 / As originally announced in October 2018, Hemogenyx-Cell S.A. ("Hemogenyx-Cell") and Immugenyx LLC ("Im
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom LaboratoryACCESS NewswireLONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company ("Janus") for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of New
- 5y agoHOPHFHemogenyx Pharmaceuticals Announces CDX Licence AgreementACCESS NewswireLONDON, UK / ACCESSWIRE / October 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the "Agreement") with the glo
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Half-Year ReportACCESS NewswireInterim Results for the period ended 30 June 2021 LONDON, UK / ACCESSWIRE / September 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the StandardListed biopharmaceutical group developing therapies designed to transform blood disease treatment, ann
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces U.S. Approval of Monoclonal Antibody PatentACCESS NewswireLONDON, UK / ACCESSWIRE / September 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a further patent application entitled MONOCLONAL A
- 5y agoELOXHOPHFHemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board ObserverACCESS NewswireDr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Ph
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC announces Corporate PresentationACCESS NewswireLONDON, UK / ACCESSWIRE / July 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce that a new corporate presentation is available at htt
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Result of Annual General MeetingACCESS NewswireLONDON, ENGLAND / ACCESSWIRE / June 25, 2021 / Hemogenyx Pharmaceuticals plc (OTC:HOPHF) (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ('AGM') held earlier today, all resolutions were duly passed. The numbers of votes for each res
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Changes to 2021 AGM ArrangementsACCESS NewswireLONDON, UK / ACCESSWIRE / June 15, 2021 / Hemogenyx Pharmaceuticals plc ('Hemogenyx Pharmaceuticals' or the 'Company')(LSE:HEMO) announces that as a result of the continuation in force of COVID-19 restrictions to 19 July announced by the UK Government, a
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC AnnouncesACCESS NewswireHemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") U.S. Approval and Issuance of CDX Antibody Patent LONDON, UK / ACCESSWIRE / June 2, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC announces Total Voting RightsACCESS NewswireLONDON, UK / ACCESSWIRE / May 28, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 cons
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Termination of Mint Facility; Admission of SharesACCESS NewswireNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURI
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Director/PDMR ShareholdingACCESS NewswireLONDON, UK / ACCESSWIRE / May 19, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC:HOPHF) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Loan Notes Sale & Conversion; Facility TerminatedACCESS NewswireNOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURI
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan NotesACCESS NewswireTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INS
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Final ResultsACCESS NewswireLONDON, UK / ACCESSWIRE / April 30, 2021 / THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE
- 5y agoHOPHFHemogenyx Pharmaceuticals PLC Announces Total Voting RightsACCESS NewswireLONDON, UK / ACCESSWIRE / April 30, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC:HOPHF), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30